Alkem Laboratories Ltd. announced its standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2025. The Board of Directors took record of these results at its meeting held in Mumbai.

In Q4 FY25, the company posted Total Revenue from Operations at Rs. 3,143.8 crore, with YoY growth of 7.1 per cent. India sales were Rs. 2, 135.5 crore, YoY growth of 8.1%. International sales were Rs.  974.7 crore, with YoY growth of 7.2 per cent.

Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were Rs. 391.3 crore, resulting in an EBITDA margin of 12.4 per cent vs. 13.7 per cent in Q4 FY24. EBITDA declined by 2.7 per cent YoY.

R&D expenses for Q4 FY25 were Rs. 158.5 crore, or 5 per cent of total revenue from operations, compared to Rs. 175.7 crore in Q4 FY24 at 6 per cent of total revenue from operations.

Net Profit (after Minority Interest) was Rs. 305.9 crore, YoY growth of 4.2 per cent.

According to IQVIA (SSA) data, for Q4FY25: The company registered a growth of 6.5% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 6.9 per cent. The acute segment growth outperformed IPM by 150 bps at 7.5 per cent.

For FY25, Alkem’s Total Revenue from Operations was Rs. 12,964.5 crore, with YoY growth of 2.3 per cent. India sales were Rs. 8,983.7 crore, with YoY growth of 6.5 per cent. International sales were Rs. 3,821 crore, with YoY de-growth of 4.5 per cent.

Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were Rs. 2,512.2 crore, resulting in an EBITDA margin of 19.4 per cent vs. 17.7 per cent in FY24. EBITDA increased by 11.9 per cent YoY.

R&D expenses for FY25 were Rs. 562 crore, or 4.3 per cent of total revenue from operations, compared to Rs. 522.9 crore in FY24 at 4.1 per cent of total revenue from operations.

 Net Profit (after Minority Interest) was Rs. 2,165.5 crore, YoY growth of 20.6 per cent.

According to IQVIA (SSA) data, for FY25: the company registered a growth of 6.8 per cent YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 7.7 per cent.

Commenting on the Q4 & FY25 results, Dr. Vikas Gupta, CEO of Alkem, said, “We ended the year on a good note, with healthy growth in our India business during Q4 and improved profitability and margins for the full year. Our domestic business continues to gain momentum, reinforcing our confidence in its long-term growth trajectory. This performance is driven by strong execution and targeted initiatives across our domestic operations. In the international businesses, excluding the Americas, we are seeing good traction, with several key markets making significant contributions to our growth. As we moved forward, we remain focused on strategic growth opportunities and operational excellence to drive sustainable returns.”